Supercharged immune cells take on Hard-to-Treat prostate cancer
NCT ID NCT03873805
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests a new type of immunotherapy for men with advanced prostate cancer that no longer responds to hormone therapy. The treatment uses the patient's own immune cells, which are genetically modified in a lab to recognize and attack cancer cells that carry a protein called PSCA. The study involves 14 participants and aims to find the safest dose and understand side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PSCA-targeting CAR-T cells (engineered immune cells) and cyclophosphamide (chemotherapy)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced prostate cancer that has stopped responding to hormone therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 14 participants, focused on safety and dosing. The treatment may not shrink tumors or extend survival, and there are risks of serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CASTRATION-RESISTANT PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a three-drug cocktail outsmart resistant prostate cancer?
- Precision radiation may tame rising PSA after prostate surgery
- Blood test could tell doctors when to stop prostate cancer treatment early
- Double-Dose precision: new combo radiation aims to shrink prostate tumors faster
- Could a stronger first dose of targeted radiation beat back advanced prostate cancer?